HT-0712

drugbox
IUPAC_name = (3"S",5"S")-5-(3-Cyclopentyloxy-4-methoxy-phenyl)-3-(3-methyl-benzyl)-piperidin-2-one


width = 160
CAS_number = 617720-02-2
synonyms = HT-0712, IPL 455,903
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C = 25 | H = 31 | N = 1 | O = 3
molecular_weight = 393.53 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in Cleveland, Ohio. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

Mechanism of action

HT-0712 appears to act as a PDE4-inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.

The side effects of the drug are not yet fully known.

Medical use

Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.

Performance enhancing use

Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.

References

[http://www.freepatentsonline.com/20040224316.html United States Patent 20040224316]

External links

* [http://www.helicontherapeutics.com/index.htm Helicon Therapeutics]
* [http://www.helicontherapeutics.com/PDFs_&_supporting_files/HT-0712_Phase_1_press_release_December_10_2004.pdf PDF file regarding Helicon's commencement of Phase I trials]
* [http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2004/03/07/wmind07.xml News article on HT-0712]